ARCH Venture Management, LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), ARCH Venture Management, LLC reported 9 stock positions worth $266.0 million. Its top holding was Beam Therapeutics (BEAM) at 47.9% of the portfolio, followed by Rapport Therapeutics (RAPP, 32.6%) and Erasca (ERAS, 9.8%). Compared with Q1 2024, it opened 2 new positions and sold out of 1. The biggest buy was a new position in Beam Therapeutics (BEAM) and the biggest sale an exit from Denali Therapeutics (DNLI).
- Most Recent 13F
- Q2 2026
- Location
- CHICAGO, IL
- CIK
- 0001274403
- Portfolio Value
- $266.0M (Q2 2024)
- SEC Filing
- 0001012975-24-000339 ↗ filed Aug 14, 2024
Holdings Value
Holdings 9 stocks · $266.0M
| BEAM Beam Therapeutics Inc. | 47.94% | 5,443,039 | $127.5M | New |
| RAPP Rapport Therapeutics Inc. | 32.60% | 3,728,738 | $86.7M | New |
| ERAS Erasca Inc. | 9.81% | 11,055,554 | $26.1M | No change |
| VERV Verve Therapeutics Inc. | 3.69% | 2,008,809 | $9.8M | No change |
| GOSS Gossamer Bio Inc. | 2.73% | 8,055,916 | $7.3M | No change |
| QTTB Q32 Bio Inc. | 2.16% | 320,482 | $5.8M | No change |
| UNBX Unity Biotechnology Inc. | 0.51% | 1,004,817 | $1.4M | No change |
| OMIC Singular Genomics Systems Inc. | 0.40% | 126,630 | $1.1M | No change |
| CERO THERAPEUTICS HLDGS INC | 0.16% | 1,444,296 | $432K | No change |
Portfolio Sells Q1 2024 → Q2 2024
| DNLI Denali Therapeutics Inc. | Sold out | 0.00% | −9.75 |
Portfolio Buys Q1 2024 → Q2 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 12 | $1.1B | PBLS, BEAM, RAPP, SPTX, ERAS |
| Q1 2026 | 10 | $677.1M | MAZE, RAPP, VIR, ERAS, BEAM |
| Q4 2025 | 9 | $651.7M | MAZE, BEAM, RAPP, LYEL, VIR |
| Q3 2025 | 9 | $492.4M | RAPP, BEAM, MAZE, VIR, LYEL |
| Q2 2025 | 11 | $299.1M | BEAM, VIR, MAZE, RAPP, VERV |
| Q1 2025 | 9 | $206.2M | BEAM, MAZE, RAPP, ERAS, VERV |
| Q4 2024 | 9 | $230.2M | BEAM, RAPP, ERAS, VERV, GOSS |
| Q3 2024 | 9 | $260.6M | BEAM, RAPP, ERAS, QTTB, VERV |
| Q2 2024 | 9 | $266.0M | BEAM, RAPP, ERAS, VERV, GOSS |
| Q1 2024 | 8 | $80.3M | VERV, ERAS, GOSS, DNLI, QTTB |